Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014:2014:568571.
doi: 10.1155/2014/568571. Epub 2014 Jul 24.

Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients

Ranganathan Natarajan  1 , Bohdan Pechenyak  1 , Usha Vyas  1 , Pari Ranganathan  1 , Alan Weinberg  2 , Peter Liang  3 , Mary C Mallappallil  3 , Allen J Norin  3 , Eli A Friedman  3 , Subodh J Saggi  3
Affiliations
Randomized Controlled Trial

Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients

Ranganathan Natarajan et al. Biomed Res Int. 2014.

Abstract

Background: Primary goal of this randomized, double-blind, placebo-controlled crossover study of Renadyl in end-stage renal disease patients was to assess the safety and efficacy of Renadyl measured through improvement in quality of life or reduction in levels of known uremic toxins. Secondary goal was to investigate the effects on several biomarkers of inflammation and oxidative stress.

Methods: Two 2-month treatment periods separated by 2-month washout and crossover, with physical examinations, venous blood testing, and quality of life questionnaires completed at each visit. Data were analyzed with SAS V9.2.

Results: 22 subjects (79%) completed the study. Observed trends were as follows (none reaching statistical significance): decline in WBC count (-0.51 × 10(9)/L, P = 0.057) and reductions in levels of C-reactive protein (-8.61 mg/L, P = 0.071) and total indoxyl glucuronide (-0.11 mg%, P = 0.058). No statistically significant changes were observed in other uremic toxin levels or measures of QOL.

Conclusions: Renadyl appeared to be safe to administer to ESRD patients on hemodialysis. Stability in QOL assessment is an encouraging result for a patient cohort in such advanced stage of kidney disease. Efficacy could not be confirmed definitively, primarily due to small sample size and low statistical power-further studies are warranted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Dysbiosis in CKD.
Figure 2
Figure 2
Study design.
See this image and copyright information in PMC

References

    1. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262–1267. - PubMed
    1. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220–230. - PMC - PubMed
    1. Kunz C, Kuntz S, Rudloff S. Intestinal flora. Advances in Experimental Medicine and Biology. 2009;639:67–79. - PubMed
    1. Relman DA. Learning about who we are. Nature. 2012;486:194–195. - PubMed
    1. Gill SR, Pop M, DeBoy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312(5778):1355–1359. - PMC - PubMed

Publication types